Home
http://www.virbac.fr/ http://www.boehringer-ingelheim.com/ http://www.novartis.com/ http://www.animalhealth.bayerhealthcare.com/
vetcontact
Vetrinär
Tiermedizin
  WELCOME  
vetcontact
Vetrinär
Tiermedizin
  Privacy Policy  
  Home  
  Login / Newsletter  
vetcontact
Vetrinär
Tiermedizin
  CONTACTS  
vetcontact
Vetrinär
Tiermedizin
  Classifieds  
  New Products  
  VetCompanies  
  VetSchools  
vetcontact
Vetrinär
Tiermedizin
  PROFESSION  
vetcontact
Vetrinär
Tiermedizin
  Edutainment  
  VetAgenda  
  Presentations  
  Posters  
  ESAVS  
  Specialisation  
vetcontact
Vetrinär
Tiermedizin
  INSIGHT  
vetcontact
Vetrinär
Tiermedizin
  Congress News  
  Picture Galleries  
vetcontact
Vetrinär
Tiermedizin
  PRODUCTS  
vetcontact
Vetrinär
Tiermedizin
  Bayer  
  Boehringer Ing.  
  Novartis  
  Virbac

 
  Simply book for less...  
    

Bovine    Equine    Small Animal Practice    Swine Practice    Articles    Vetjournal    
deutsch english espaņol polski francais
Home / WELCOME / Archiv / Equine /     
 
New vaccines against West Nile virus infection
West Nile virus (WNV) infection is endemic and able to cause disease in naive hosts. Also humans can be infected - for them remaining indoor during the flight time of mosquitoes and/or use of repellents is recommended. Horses can be vaccinated. Some vaccines are availabel. What about the safety of new vaccines?

This study was performed to establish: 1) the safety of a modified live Flavivirus/West Nile virus (WN-FV) chimera by administration of an overdose and testing for shed of vaccine virus and spread to uninoculated sentinel horses; 2) that this vaccine did not become pathogenic once passaged in horses; and 3) vaccine safety under field conditions.

There were 3 protocols: 1) In the overdose/shed and spread study, horses were vaccinated with a 100x immunogenicity overdose of WN-FV chimera vaccine and housed with sentinel horses. 2) A reversion to virulence study, where horses were vaccinated with a 20x immunogenicity overdose of WN-FV chimera vaccine. Horses in both studies were evaluated for abnormal health conditions and samples obtained to detect virus, seroconversion and dissemination into tissues. 3) In a field safety test 919 healthy horses of various ages, breeds and sex were used.

RESULTS: Vaccination did not result in site or systemic reactions in either experimental or field-injected horses.
There was no shed of vaccine virus, no detection of vaccine virus into tissue and no reversion to virulence with passage.

CONCLUSIONS: WN-FV chimera vaccine is safe to use in horses with no evidence of ill effects from very high doses of vaccine.
There was no evidence of reversion to virulence. In addition, administration of this vaccine to several hundred horses that may have been previously exposed to WNV or WNV vaccine resulted in no untoward reactions.
These studies establish that this live attenuated Flavivirus chimera is safe to use for immunoprophylaxis against WNV disease in horses.




Tell a friend   |   Print version   |   Send this article

EQUINE

Valacyclovir in horses with equine multinodular pulmonary fibrosismembers
Equine herpesvirus‐5 is commonly isolated from the lungs of horses with EMPF, suggesting an etiological link. Valacyclovir is used empirically to treat EMPF; however, no data is available concerning its impact on EHV‐5 viral kinetics. The objectives of this study were to determine the effect of oral administration of valacyclovir on EHV‐5 viral load measured by qPCR in blood, nasal secretions (NS) and BALF in horses with EMPF on six horses diagnosed with EMPF.

  • Radiculopathy associated with forelimb lameness in horsesmembers
  • Biological variations of routine blood parameters in horsesmembers
  • Prognosis for horses with deep digital flexor tendon injury after penetrating woundmembers
  • Possible maternal effect for the pace trait of horsesmembers
  • Flecainide on induced atrial fibrillation in horsesmembers
  • Sonographic technique to identify manica flexoria tears in horsesmembers
  • Novel prototype dynamic laryngoplasty system on arytenoid abductionmembers
  • Lipid peroxidation biomarkers in equine neuroaxonal dystrophymembers
  • Eosinophils of the horse: an updatemembers
  • Presumed Neuroglycopenia following Severe Hypoglycemia in Horsesmembers
  • E321G MYH1 mutation and nonexertional rhabdomyolysis in Quarter Horsesmembers
  • Novel therapeutic approach for mares with suspected uterine tubal blockagemembers


  • [ Home ] [ About ] [ Contact / Request ] [ Privacy Policy ]

    Copyright © 2001-2018 VetContact GmbH
    All rights reserved